Skip to content
Markets
SPY731.00▼ -0.20%QQQ659.93▲ +0.45%DIA501.60▼ -1.13%GLD341.51▼ -3.11%TLT80.19▲ +0.80%BABA85.58▼ -1.23%NIO2.83▲ +0.53%PDD77.50▲ +0.14%Realtime derived data
Octans ResearchOCTANS RESEARCHWaitlist
Looking up at 14 Wall Street and neighboring office towers in Lower Manhattan's Financial District on a cloudy day.
Source: Jakembradford, CC BY-SA 4.0, via Wikimedia Commons

Kura Oncology CEO Troy Edward Wilson buys $1.5 million of shares

Open market purchase reported on Form 4, filed Nov 16, 2026.

Octans ResearchPublished

Snapshot

Troy Edward Wilson, President and CEO of Kura Oncology (KURA), bought 200,000 shares in open market purchases between Nov 13, 2026 and Nov 16, 2026, about $1.5 million at an average price of $7.52 a share, according to a Form 4 filed with the SEC on Nov 16, 2026.

Coverage
Independent Research
Prepared by
Octans Research
Tickers
KURA
As of

Market Data

Latest prices for the companies covered in this article
Company1D %Price
($KURA)▼ −1.07%7.41

as of 14:32 ET · Realtime derived data

What We Know

The filing lists 2 open market purchase lines: • Nov 13, 2026: 98,881 shares at $7.63. • Nov 16, 2026: 101,119 shares at $7.42.

After the last purchase, the filing reports 635,456 shares held directly in that account.

Octans View

The purchases raised the holding reported in that account by about 46%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought.

Bear Case · Room for Disagreement

Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.

Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.

Chart

$KURA adjusted close, last 6 months $KURA adjusted close, last 6 months: series falling from 11.3 to 7.5 (−33.4%) from 2026-05-22 to 2026-11-17. Scale 6 to 14. 68101214 2026-05-222026-11-17 $KURA ADJUSTED CLOSE, LAST 6 MONTHS −33.4% 7.49
Source: Tiingo · As of 2026-11-17Indicative, not investment advice.

Sources

  1. [1]SEC EDGAR — Form 4 filed by Troy Edward Wilson for Kura Oncology, Nov 16, 2026

These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.

$1.5M

Troy Edward Wilson, President and CEO of Kura Oncology (KURA), bought 200,000 shares in open ma… · Snapshot

Related coverage

More on $KURA

4 reports